首页> 外文期刊>The breast journal >Complex sclerosing lesions and radial sclerosing lesions on core needle biopsy: Low risk of carcinoma on excision in cases with clinical and imaging concordance
【24h】

Complex sclerosing lesions and radial sclerosing lesions on core needle biopsy: Low risk of carcinoma on excision in cases with clinical and imaging concordance

机译:核心针活检的复杂硬化病变和径向硬化病变:临床和成像协调案例中切除癌的低风险

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Complex or radial sclerosing lesions ( CSL / RSL ) are uncommon diagnoses on core needle biopsy with a reported upgrade rate ranging between 0% and 23%. As a result, their management remains controversial. In this study, we sought to determine the rate of malignancy on excision for patients with pure CSL / RSL on core biopsy, and to evaluate future breast cancer risk when CSL / RSL is managed without excision. We retrospectively reviewed 118 cases of CSL / RSL diagnosed on image‐guided breast biopsies between 2005 and 2014 at our institution. Of 98 analyzed patients, 34 (35%) underwent excision and 64 (65%) were observed. Demographic and clinical variables between excision and observation groups were compared. In excised specimens, factors associated with upgrade to malignancy were evaluated. The median age at diagnosis was 49 years (range, 27‐88 years). In the excision group, 3/34 cases were associated with malignancy, an overall upgrade rate of 9%. All malignant cases had core needle biopsies interpreted as discordant and were BIRADS 4B or more on imaging. In the observation group, at a median follow‐up of 2.2 years, 3/64 (5%) patients developed ipsilateral cancers, all of which were distant from the index CSL / RSL . In our series, we report a 9% malignancy rate on excision of BIRADS 4C lesions characterized as CSL / RSL on core biopsy. In patients with concordant biopsies and BIRADS 4A or lower lesions who underwent observation, we found a low rate of subsequent ipsilateral cancers. Further studies are needed to confirm that for CSL / RSL in concordant core biopsies and BIRADS 4A or lower, nonpalpable lesions, observation may be a reasonable alternative to excision.
机译:摘要复合物或径向硬化病变(CSL / RSL)在核心针活检上罕见诊断,报告的升级率在0%和23%之间。结果,他们的管理层仍然存在争议。在这项研究中,我们试图确定核心活检纯CSL / RSL患者切除切除率的恶性肿瘤率,并在没有切除的情况下管理CSL / RSL时评估未来的乳腺癌风险。我们回顾性地审查了在我们的机构2005年至2014年期间诊断出诊断的118例CSL / RSL案例。在98例分析的患者中,观察到34(35%)接受切除和64(65%)。比较了切除和观察组之间的人口和临床变量。在切除的标本中,评估与升级到恶性肿瘤相关的因素。诊断中位年龄为49岁(范围,27-88岁)。在切除组中,3/34例与恶性肿瘤有关,总升级率为9%。所有恶性病例都有核心针活检,被认为是不和谐的,并且在成像中是Birads 4b或更多。在观察组中,在2.2岁的中期随访中,3/64(5%)患者开发了同侧癌症,所有这些癌症都与指数CSL / RSL远离。在我们的系列中,我们在Birads和GT切除切除的情况下报告了9%的恶性率。4C病变,其特征在于核心活检的CSL / RSL。在接受观察的一致性活组织检查和Birad 4a或较低病变的患者中,我们发现随后的同侧癌症的低速率。需要进一步的研究来证实,对于CSL / RSL,CSL / RSL在一致的核心活组织检查和Birads 4a或更低,非耐受性病变,观察可能是切除的合理替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号